Literature DB >> 8676964

Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia.

R Peces, M de la Torre, R Alcázar, J M Urra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8676964     DOI： 10.1056/NEJM199608153350717

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Current methods for detecting antibodies against erythropoietin and other recombinant proteins.

Authors:  Robin Thorpe; Steven J Swanson
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

Review 2.  Emerging erythropoiesis-stimulating agents.

Authors:  Robert N Foley
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 3.  Today's challenges in pharmacovigilance: what can we learn from epoetins?

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Huub Schellekens; Hubert G Leufkens
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

4.  An insight into the thermodynamic characteristics of human thrombopoietin complexation with TN1 antibody.

Authors:  Shigeki Arai; Chie Shibazaki; Motoyasu Adachi; Eijiro Honjo; Taro Tamada; Yoshitake Maeda; Tomoyuki Tahara; Takashi Kato; Hiroshi Miyazaki; Michael Blaber; Ryota Kuroki
Journal:  Protein Sci       Date:  2016-07-25       Impact factor: 6.725

5.  Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal:  Blood       Date:  2005-08-11       Impact factor: 22.113

6.  Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.

Authors:  Melita Buljan; Damir Nemet; Branka Golubic-Cepulic; Goran Bicanic; Branko Tripkovic; Domagoj Delimar
Journal:  Int Orthop       Date:  2011-10-01       Impact factor: 3.075

7.  Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution.

Authors:  Angel Alonso Melgar; Marta Melgosa Hijosa; Rafael Pardo de la Vega; Carmen García Meseguer; Mercedes Navarro Torres
Journal:  Pediatr Nephrol       Date:  2004-05-07       Impact factor: 3.714

Review 8.  State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.

Authors:  Adrian Covic; Ivo Abraham
Journal:  Int Urol Nephrol       Date:  2015-07-30       Impact factor: 2.370

9.  Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient.

Authors:  Parnell Mattison; Kiran Upadhyay; Jennifer E Wilcox; Asha Moudgil; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2010-01-21       Impact factor: 3.714

Review 10.  Epoetin-associated pure red cell aplasia: past, present, and future considerations.

Authors:  June M McKoy; Robin E Stonecash; Denis Cournoyer; Jerome Rossert; Allen R Nissenson; Dennis W Raisch; Nicole Casadevall; Charles L Bennett
Journal:  Transfusion       Date:  2008-05-14       Impact factor: 3.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.